http://www.tcsurg.org/article/10.7507/1007-4848.202403024 WebSep 10, 2024 · plasmaMATCH is, to our knowledge, the first large, prospective, multicentre study assessing the feasibility and clinical utility of ctDNA analysis to direct therapy in …
Oral selective estrogen receptor degraders DDDT
WebFeature. The Medical Clinical Trials database is the most comprehensive clinical trials database in the market. Benefit. Covers planned, ongoing, completed and terminated / suspended / withdrawn trials, and outlines information regarding trial type, study design, objective, end points, patient details, results, investigators, locations, contact details, and … WebWhat is the aim of the plasmaMATCH trial? Breast cancers release DNA into the blood. We can analyse this circulating tumour DNA (ctDNA) via a simple blood test, known as a ‘liquid biopsy’. memorial hermann the woodlands phone number
Major ‘plasmaMATCH’ trial uses blood test to match …
WebHere we present analysis of baseline and end-of-treatment (EOT) ctDNA to identify potential resistance mutations to fulvestrant. Methods: Paired baseline and EOT plasma samples from patients enrolled into plasmaMATCH underwent ctDNA sequencing (Guardant360, Guardant Health) to identify acquired mutations. WebNov 1, 2024 · This report from the plasmaMATCH trial, coordinated by the Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU), was published in Nature Communications and funded by... WebFeb 15, 2024 · This analysis describes the genomic landscape of ctDNA in patients screened for the UK plasmaMATCH study. Methods: The plasmaMATCH trial was an open-label, multi-centre, multi-cohort platform trial, consisting of ctDNA testing in ~1000 patients with advanced BC. The trial consists of parallel treatment cohorts (Cohorts A-E) with therapies ... memorial hermann the woodlands breast imaging